High-throughput screening and selection of mammalian cells for enhanced protein production

2016 ◽  
Vol 11 (7) ◽  
pp. 853-865 ◽  
Author(s):  
Joseph J. Priola ◽  
Nathan Calzadilla ◽  
Martina Baumann ◽  
Nicole Borth ◽  
Christopher G. Tate ◽  
...  
2005 ◽  
pp. 4167 ◽  
Author(s):  
Edel M. Minogue ◽  
Tammy P. Taylor ◽  
Anthony K. Burrell ◽  
George J. Havrilla ◽  
Benjamin P. Warner ◽  
...  

Author(s):  
Sarah M. Rue ◽  
Paul W. Anderson ◽  
Michelle R. Gaylord ◽  
Jessica J. Miller ◽  
Scott M. Glaser ◽  
...  

2020 ◽  
Vol 16 (1) ◽  
pp. 13-23
Author(s):  
Nazmina Vhora ◽  
Ujjal Naskar ◽  
Aishwarya Hiray ◽  
Abhijeet S. Kate ◽  
Alok Jain

BACKGROUND: A higher rate of attenuation of molecules in drug discovery has enabled pharmaceutical companies to enhance the efficiency of their hit identification and lead optimization. Selection and development of appropriate in-vitro and in-vivo strategies may improve this process as primary and secondary screening utilize both strategies. In-vivo approaches are too relentless and expensive for assessing hits. Therefore, it has become indispensable to develop and implement suitable in-vitro screening methods to execute the required activities and meet the respective targets. However, the selection of an appropriate in-vitro assay for specific evaluation of cellular activity is no trivial task. It requires thorough investigation of the various parameters involved. AIM: In this review, we aim to discuss in-vitro assays for type 2 diabetes (T2D), which have been utilized extensively by researchers over the last five years, including target-based, non-target based, low-throughput, and high-throughput screening assays. METHODS: The literature search was conducted using databases including Scifinder, PubMed, ScienceDirect, and Google Scholar to find the significant published articles. DISCUSSION and CONCLUSION: The accuracy and relevance of in-vitro assays have a significant impact on the drug discovery process for T2D, especially in assessing the antidiabetic activity of compounds and identifying the site of effect in high-throughput screening. The report reviews the advantages, limitations, quality parameters, and applications of the probed invitro assays, and compares them with one another to enable the selection of the optimal method for any purpose. The information on these assays will accelerate numerous procedures in the drug development process with consistent quality and accuracy.


2009 ◽  
Vol 2 (1) ◽  
pp. 63 ◽  
Author(s):  
Hanna-Riikka Kärkkäinen ◽  
Hanna P Lesch ◽  
Antti I Määttä ◽  
Pyry I Toivanen ◽  
Anssi J Mähönen ◽  
...  

Cryobiology ◽  
2016 ◽  
Vol 73 (3) ◽  
pp. 425
Author(s):  
P. Kilbride ◽  
E. Thompson ◽  
M. Ryan ◽  
K. Mahbubani ◽  
B. Luke ◽  
...  

2018 ◽  
Vol 3 (1) ◽  
Author(s):  
Luis E Contreras-Llano ◽  
Cheemeng Tan

Abstract The incorporation of cell-free transcription and translation systems into high-throughput screening applications enables the in situ and on-demand expression of peptides and proteins. Coupled with modern microfluidic technology, the cell-free methods allow the screening, directed evolution and selection of desired biomolecules in minimal volumes within a short timescale. Cell-free high-throughput screening applications are classified broadly into in vitro display and on-chip technologies. In this review, we outline the development of cell-free high-throughput screening methods. We further discuss operating principles and representative applications of each screening method. The cell-free high-throughput screening methods may be advanced by the future development of new cell-free systems, miniaturization approaches, and automation technologies.


Sign in / Sign up

Export Citation Format

Share Document